News Search Results

« Previous 12345 Next »
Viewing Page 1 of 28 | Showing Results 1 - 10 of 275

Melanoma study: are two immunotherapies better than one?

December 07, 2018

A newly opened Phase 3 study at Providence Cancer Institute hopes to shed new light on the benefits of two immunotherapies, nivolumab and NKTR-214, for patients with advanced melanoma.

Introducing Providence St. Joseph Health Digital Commons

December 06, 2018

Providence St. Joseph Health (PSJH) recently launched a new platform to highlight the scholarly activities of its providers, researchers and caregivers: Digital Commons. The institutional repository serves as a singular site to easily access and navigate PSJH journal articles, abstracts, book chapters, presentations and other materials.

New immunotherapy options for liver cancer

November 29, 2018

Checkpoint inhibitors are showing promise as a potential new line of treatment for people with liver cancer. The Earle A. Chiles Research Institute at Providence Cancer Institute currently has six studies open to liver cancer patients, including two new studies investigating checkpoint inhibitors.

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

October 17, 2018

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute.

The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed!

October 02, 2018

The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed! This new space allows us to expand and consolidate our outpatient cancer services in the new Providence Cancer Institute Franz Clinic.

Nobel Prize Honors Immunotherapy Researchers; Work Included Clinical Trials Led by Providence Dr. Walter Urba

October 02, 2018

The announcement that the Nobel Prize in Medicine has been awarded to two cancer immunotherapy researchers is a significant acknowledgement of the effect of immunotherapy and the work that has been done by the Providence team lead by Walter J. Urba, M.D., Ph.D., director of Earle A. Chiles Research Institute and Robert W. Franz Cancer Center for the last two decades.

PARP-inhibitor study opens for BRCA+, HER2- breast cancer

October 01, 2018

PARP inhibitors are emerging as “one of the promising breakthroughs in experimental oncology,” and have the potential to offer significant benefits for women with BRCA-mutant breast cancers.

Visiting Japanese students see health care at work at Providence Portland

September 18, 2018

Last month our Providence School Outreach team organized a gathering of caregivers from Providence Portland to meet with students from Nihon Institute of Medical Science.

Providence Cancer Institute Franz Clinic offers expanded outpatient services

September 14, 2018

From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That's why we have expanded and consolidated outpatient cancer services on the 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center.

Kendall Sawa Named New Chief Operating Officer of Providence Portland Medical Center

September 12, 2018

Kendall Sawa has been named chief operating officer for Providence Portland Medical Center. Sawa currently serves as the chief executive for Providence Seaside Hospital and North Coast Service Area. He will begin his new role Nov. 5.

« Previous 12345 Next »
Viewing Page 1 of 28 | Showing Results 1 - 10 of 275